Cerebrospinal fluid tau and Abeta42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment

N Andreasen; Lennart Minthon; E Vanmechelen; H Vanderstichele; P Davidsson; B Winblad; K Blennow

doi:10.1016/S0304-3940(99)00617-5

Cerebrospinal fluid tau and Abeta42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment

N Andreasen, Lennart Minthon, E Vanmechelen, H Vanderstichele, P Davidsson, B Winblad, K Blennow

Department of Clinical Sciences, Malmö

Research output: Contribution to journal › Article › peer-review

Abstract

We studied CSF-tau and CSF-Abeta42 in 16 patients with mild cognitive impairment (MCI) who at follow-up investigations 6-27 months later had progressed to Alzheimer's disease (AD) with dementia. For comparison, we studied 15 age-matched healthy individuals. At baseline, 14/16 (88%) of MCI patients had high CSF-tau and/or low CSF-Abeta42 levels. These findings show that these CSF-markers are abnormal before the onset of clinical dementia and that they may help to identify MCI patients that will develop AD. This is especially important when drugs with potential effects on the progression of AD will reach the clinical phase.

Original language	English
Pages (from-to)	5-8
Journal	Neuroscience Letters
Volume	273
Issue number	1
DOIs	https://doi.org/10.1016/S0304-3940(99)00617-5
Publication status	Published - 1999

Subject classification (UKÄ)

Neurosciences

Access to Document

10.1016/S0304-3940(99)00617-5

Cite this

@article{6cfde8002612489798c85486614d215a,

title = "Cerebrospinal fluid tau and Abeta42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment",

abstract = "We studied CSF-tau and CSF-Abeta42 in 16 patients with mild cognitive impairment (MCI) who at follow-up investigations 6-27 months later had progressed to Alzheimer's disease (AD) with dementia. For comparison, we studied 15 age-matched healthy individuals. At baseline, 14/16 (88%) of MCI patients had high CSF-tau and/or low CSF-Abeta42 levels. These findings show that these CSF-markers are abnormal before the onset of clinical dementia and that they may help to identify MCI patients that will develop AD. This is especially important when drugs with potential effects on the progression of AD will reach the clinical phase.",

author = "N Andreasen and Lennart Minthon and E Vanmechelen and H Vanderstichele and P Davidsson and B Winblad and K Blennow",

year = "1999",

doi = "10.1016/S0304-3940(99)00617-5",

language = "English",

volume = "273",

pages = "5--8",

journal = "Neuroscience Letters",

issn = "0304-3940",

publisher = "Elsevier",

number = "1",

}

TY - JOUR

T1 - Cerebrospinal fluid tau and Abeta42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment

AU - Andreasen, N

AU - Minthon, Lennart

AU - Vanmechelen, E

AU - Vanderstichele, H

AU - Davidsson, P

AU - Winblad, B

AU - Blennow, K

PY - 1999

Y1 - 1999

N2 - We studied CSF-tau and CSF-Abeta42 in 16 patients with mild cognitive impairment (MCI) who at follow-up investigations 6-27 months later had progressed to Alzheimer's disease (AD) with dementia. For comparison, we studied 15 age-matched healthy individuals. At baseline, 14/16 (88%) of MCI patients had high CSF-tau and/or low CSF-Abeta42 levels. These findings show that these CSF-markers are abnormal before the onset of clinical dementia and that they may help to identify MCI patients that will develop AD. This is especially important when drugs with potential effects on the progression of AD will reach the clinical phase.

AB - We studied CSF-tau and CSF-Abeta42 in 16 patients with mild cognitive impairment (MCI) who at follow-up investigations 6-27 months later had progressed to Alzheimer's disease (AD) with dementia. For comparison, we studied 15 age-matched healthy individuals. At baseline, 14/16 (88%) of MCI patients had high CSF-tau and/or low CSF-Abeta42 levels. These findings show that these CSF-markers are abnormal before the onset of clinical dementia and that they may help to identify MCI patients that will develop AD. This is especially important when drugs with potential effects on the progression of AD will reach the clinical phase.

U2 - 10.1016/S0304-3940(99)00617-5

DO - 10.1016/S0304-3940(99)00617-5

M3 - Article

SN - 0304-3940

VL - 273

SP - 5

EP - 8

JO - Neuroscience Letters

JF - Neuroscience Letters

IS - 1

ER -

Cerebrospinal fluid tau and Abeta42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment

Abstract

Subject classification (UKÄ)

Access to Document

Fingerprint

Cite this